Wakey-wakey, everyone. It’s Friday! You can sip your cup of stimulation with satisfaction this morning: You made it through another week. Nick Florko here, filling in for the great Ed Silverman. We are all out of exciting sipping choices here, so straight espresso will have to do. We are hopeful, however, that the afternoon may bring some more scintillating options: A tamarind espresso tonic, perhaps? Time will tell. Here are a few items of interest to get you through that last trudge before the weekend. …
The Food and Drug Administration expects to have a plan on Covid-19 boosters by early September, the Wall Street Journal reports. The plan is likely to lay out who should receive boosters and when, sources tell the Journal. Pfizer (PFE) is expected to ask the FDA this month for authorization to sell booster shots. Moderna (MRNA) is expected to do the same in September.
The federal government will halt funding of Novavax’s (NVAX) Covid-19 vaccine production until the company resolves concerns of federal regulators, the New York Times reports. The company, which nabbed a $1.75 billion federal contract to develop and produce a vaccine, has been unable to satisfy FDA regulators. The problem, it seems, relates to the company’s analytic testing methods, according to a filing with the SEC.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect